Proposal for MCC950 (CP-456,773; Sigma-Aldrich, catalog #SML 2233)

Overview of Therapeutic Candidate:
MCC950, also known as CP-456,773, is a synthetic small-molecule drug originally developed as one of the first highly selective inhibitors of the NLRP3 inflammasome. It belongs to the diarylsulfonylurea class of compounds, which emerged from medicinal chemistry efforts that initially focused on sulfonylurea drugs such as glyburide. Glyburide was found to have anti‐inflammatory properties mediated by inhibition of the NLRP3 complex; however, its clinical utility as an anti-inflammatory agent was limited by its potent effects on insulin release and the consequent risk of hypoglycemia. To overcome these limitations, researchers refined the chemical structure and synthesized MCC950, a derivative that retains the inflammasome inhibitory activity of glyburide without disturbing insulin secretion. The design of MCC950 was based on structure–activity relationship studies that identified the importance of the diarylsulfonylurea moiety, and its eventual discovery positioned it as a gold-standard benchmark compound for NLRP3 inhibition (Kaur et al., 2025; Coll et al., 2019). This compound has been synthesized and purified by several vendors including Sigma-Aldrich (catalog #SML 2233), ensuring reproducibility and accessibility to research teams. Overall, MCC950 represents a promising example of rational drug design aimed at selectively targeting components of the innate immune system and addressing the inflammatory cascades that contribute to disease pathology.

Therapeutic History:
The therapeutic history of MCC950 is marked by extensive preclinical evidence spanning animal models of a wide array of inflammatory disorders. Initially investigated in models of auto-inflammatory diseases and neurodegenerative disorders, MCC950 quickly emerged as the benchmark inhibitor for studying NLRP3 inflammasome–mediated inflammation. In rodent models of kidney diseases, including diabetic nephropathy, salt-sensitive hypertension, and adenine-induced chronic renal failure, MCC950 has demonstrated significant reductions in proteinuria, attenuated fibrosis, and improvements in overall renal function (Krishnan et al., 2019; Li et al., 2019). Preclinical studies conducted in diabetic models have shown that chronic treatment with MCC950 leads to marked improvements in histopathological kidney damage, as evidenced by reduced mesangial expansion and decreased podocyte injury (Zhang et al., 2019). In addition, rodent studies in salt-sensitive hypertensive models reveal that inhibition of the NLRP3 inflammasome via MCC950 results in lower blood pressure, decreased interstitial inflammatory infiltrates, and reduced collagen deposition in renal tissues (Krishnan et al., 2019; Wang et al., 2025). Although robust evidence from animal studies supports its efficacy in models of chronic kidney disease (CKD), clinical translation remains limited with only sparse early-phase clinical trials referenced in the literature (ClinicalTrials.gov). Additionally, the favorable safety profile observed in non-human primate studies further underpins its potential for repurposing in CKD, although more clinical data are needed to fully establish its benefit–risk profile.

Mechanism of Action:
MCC950’s mechanism of action is both specific and well-characterized at the molecular level. The compound exerts its inhibitory effect by directly binding to the Walker B motif located within the NACHT domain of the NLRP3 protein. This binding interferes with the ATP hydrolysis that is essential for NLRP3 activation and subsequent oligomerization of the inflammasome complex (Coll et al., 2019; Yuan et al., 2022). Under normal pathological conditions, activation of the NLRP3 inflammasome leads to the recruitment of the adaptor protein ASC and the cleavage of pro-caspase-1 into its active form. Active caspase-1 then processes pro-inflammatory cytokines, particularly interleukin-1β (IL-1β) and interleukin-18 (IL-18), into their mature forms and also initiates gasdermin D-mediated pyroptosis—a form of inflammatory cell death. By preventing ATP hydrolysis, MCC950 locks NLRP3 in an inactive conformation, thereby obstructing the assembly of the entire inflammasome complex, reducing caspase-1 activation and cytokine maturation (Kim et al., 2019; Zhan et al., 2023). In the context of human tubular epithelial cells (TECs), which express NLRP3 and contribute to renal inflammatory cascades, MCC950’s engagement with the Walker B motif is proposed to significantly curb inflammasome formation. Such direct target engagement has been validated by surface plasmon resonance (SPR) and mutagenesis assays that confirm the drug’s specificity and potency. Blocking inflammasome assembly not only reduces cytokine release but also limits the formation of gasdermin D pores that are responsible for pyroptotic cell death, thereby preventing tubular cell loss and reducing interstitial inflammation (Liu et al., 2021; Yang et al., 2019).

Expected Effect:
Given its robust preclinical evidence, the expected effect of MCC950 in assays focusing on CKD and related kidney injury is multifaceted. In in vitro models using human TECs, the hypothesis is that treatment with MCC950 will prevent ATP hydrolysis, thereby inhibiting NLRP3 inflammasome assembly and subsequent caspase-1 activation. As a result, the maturation and release of IL-1β and IL-18 will be significantly reduced, ultimately leading to lower levels of pyroptosis, attenuation of inflammation, and prevention of the fibrotic remodeling that often accompanies progressive CKD (Krishnan et al., 2019; Li et al., 2019). In vivo, these effects are anticipated to manifest as decreased proteinuria, improved kidney function markers, reduced inflammatory cell infiltration, and lower extracellular matrix deposition. This translates into a reduction in renal interstitial fibrosis and a preservation of normal tubular architecture, thereby ameliorating the progressive decline in renal function seen in CKD models. The expression profile of NLRP3 in TECs, coupled with its established role in mediating inflammatory and fibrotic responses, provides a solid rationale for targeting NLRP3 in chronic kidney disease (Zhang et al., 2019; Yuan et al., 2022). The proposed mechanism is in alignment with the pathological features of CKD, where sustained low-grade inflammation and fibrosis lead to irreversible kidney damage.

Overall Evaluation:
MCC950 represents a highly promising therapeutic candidate for the treatment of chronic kidney disease due to several compelling strengths. First, its rational design as a selective NLRP3 inhibitor ensures that it directly targets a critical inflammatory pathway implicated in the pathogenesis of CKD. The extensive preclinical evidence in diverse animal models—from diabetic nephropathy to salt-sensitive hypertension and adenine-induced renal failure—strongly supports its renoprotective effects, including reductions in proteinuria, improved renal function, and diminished fibrotic remodeling (Krishnan et al., 2019; Li et al., 2019; Sabra et al., 2023). Second, the detailed elucidation of its molecular mechanism—confirming binding to the Walker B motif in the NACHT domain of NLRP3 and preventing ATP hydrolysis—provides a clear mechanistic rationale that is essential for translational development (Coll et al., 2019; Yuan et al., 2022). Third, its favorable pharmacological properties, including oral bioavailability and a safety profile established in non-human primates, further underline its developmental feasibility (Kaur et al., 2025; ClinicalTrials.gov).

However, there are some potential weaknesses that must be carefully considered. Although rodent models have provided robust efficacy data, the translation of these effects to humans remains to be fully validated. There is a paucity of comprehensive clinical trials specifically targeting CKD with MCC950, which introduces uncertainty regarding its efficacy and potential off-target effects in a human patient population. Additionally, while the compound is highly selective for the NLRP3 inflammasome, it is critical to further elucidate its long-term safety and impact on global immune function, given the essential role of inflammasomes in host defense. In some experimental contexts, there has been variability in the inhibition of inflammation and fibrosis depending on the specific disease model, suggesting that its therapeutic window may differ based on disease etiology (Sabra et al., 2023). Despite these challenges, the overall evidence supports the further development of MCC950 as a mechanistic intervention in CKD, particularly in settings where inflammasome-driven pathology is predominant.

In summary, MCC950 is a well-characterized, rationally designed NLRP3 inhibitor with strong preclinical evidence demonstrating its renoprotective effects in various models of chronic kidney disease. Its specific binding to the Walker B motif of the NLRP3 NACHT domain and subsequent inhibition of ATP hydrolysis form the basis of its mechanism, reducing caspase-1 activation, IL-1β/IL-18 maturation, and gasdermin-D-mediated pyroptosis. These actions are expected to translate into reduced tubular epithelial cell death, diminished interstitial inflammation, and alleviation of fibrotic remodeling—key pathological processes in CKD progression. While further clinical validation is necessary, the strengths in mechanistic rationale, preclinical efficacy data, and favorable pharmacokinetic properties position MCC950 as a highly promising therapeutic candidate for repurposing in chronic kidney disease (Coll et al., 2019; Kim et al., 2019; Krishnan et al., 2019; Yuan et al., 2022).

References
Coll, R. C., Hill, J. R., Day, C. J., Zamoshnikova, A., Boucher, D., Massey, N. L., Chitty, J. L., Fraser, J. A., Jennings, M. P., Robertson, A. A. B., & Schroder, K. (2019). MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nature Chemical Biology, 15, 556–559. https://doi.org/10.1038/s41589-019-0277-7

ClinicalTrials.gov. (n.d.). Search for MCC950 OR CP-456,773 OR NLRP3 inhibitor AND (chronic kidney disease OR CKD OR kidney fibrosis OR nephropathy). Retrieved from https://clinicaltrials.gov

Kaur, B., Biby, S., Namme, J. N., More, S., Xu, Y., & Zhang, S. (2025). Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain‐penetrant inhibitors. Advances in Pharmacology, 102, 103–157. https://doi.org/10.1016/bs.apha.2024.10.004

Kim, Y. G., Kim, S.-M., Kim, K.-P., Lee, S.-H., & Moon, J.-Y. (2019). The role of inflammasome-dependent and inflammasome-independent NLRP3 in the kidney. Cells, 8(11), 1389. https://doi.org/10.3390/cells8111389

Krishnan, S. M., Ling, Y. H., Huuskes, B. M., Ferens, D. M., Saini, N., Chan, C. T., Diep, H., Kett, M. M., Samuel, C. S., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Peter, K., Latz, E., Mansell, A. S., Sobey, C. G., Drummond, G. R., & Vinh, A. (2019). Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovascular Research, 115, 776–787. https://doi.org/10.1093/cvr/cvy252

Li, S., Lin, Q., Shao, X., Mou, S., Gu, L., Wang, L., Zhang, Z., Shen, J., Zhou, Y., Qi, C., Jin, H., Pang, H., & Ni, Z. (2019). NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation. Experimental Cell Research, 383, 111488. https://doi.org/10.1016/j.yexcr.2019.07.001

Liu, Z., Chen, Y., Niu, B., Yin, D., Feng, F., Gu, S., An, Q., Xu, J., An, N., Zhang, J., Yi, J., Yin, W., Qin, X., & Hu, X. (2021). NLRP3 inflammasome of renal tubular epithelial cells induces kidney injury in acute hemolytic transfusion reactions. Clinical and Translational Medicine, 11. https://doi.org/10.1002/ctm2.373

Sabra, M. S., Hemida, F. K., & Allam, E. A. H. (2023). Adenine model of chronic renal failure in rats to determine whether MCC950, an NLRP3 inflammasome inhibitor, is a renopreventive. BMC Nephrology. https://doi.org/10.1186/s12882-023-03427-4

Wang, Y., Wu, Y., Ren, J., Wang, Y., Perwaiz, I., Su, H., Li, J., & Qu, P. (2025). Pharmacological inhibition of the NLRP3 inflammasome attenuates kidney apoptosis, fibrosis, and injury in Dahl salt-sensitive rats. Clinical and Experimental Nephrology, 29, 113–122. https://doi.org/10.1007/s10157-024-02567-7

Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death & Disease, 10, Article 128. https://doi.org/10.1038/s41419-019-1413-8

Yuan, Q., Tang, B., & Zhang, C. (2022). Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduction and Targeted Therapy, 7, Article 204. https://doi.org/10.1038/s41392-022-01036-5

Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023). The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors. Frontiers in Immunology, 13, 1109938. https://doi.org/10.3389/fimmu.2022.1109938

Zhang, C., Zhu, X., Li, L., Ma, T.-M., Shi, M., Yang, Y., & Fan, Q. (2019). A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12, 1297–1309. https://doi.org/10.2147/DMSO.S199802
